DiscGenics Treats First Patient in IDCT Trial

The first patient has been treated in DiscGenics' Phase I/II U.S. clinical trial of IDCT injection to treat mild to moderate degenerative disc disease.

IDCT is an allogeneic cell therapy comprising Discogenic Cells and a viscous scaffold. During treatment, a dose of IDCT is injected percutaneously into the disc. The prospective, randomized,...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0